Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

Details of the presentations are as follows:

Title: A Phase 1/2 Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Adults with ENPP1 Deficiency
Format: Poster Presentation
Dates: Friday, October 13, 2023/Sunday, October 15, 2023
Session Times: 6:00-7:30 p.m. PT/ 1:30-3:00 p.m. PT
Author/Presenter: Yves Sabbagh, Ph.D. (Senior Vice President and Chief Scientific Officer, Inozyme Pharma)

Title: A Phase 1/2 Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults with ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE): An Interim Analysis
Format: Poster Presentation
Dates: Friday, October 13, 2023/Saturday, October 14, 2023
Session Times: 6:00-7:00 p.m. PT/ 1:30-3:00 p.m. PT
Author/Presenter: Yves Sabbagh, Ph.D. (Senior Vice President and Chief Scientific Officer, Inozyme Pharma)

Title: ENPP1 enzyme replacement therapy improves brain calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia
Format: Poster Presentation
Date: Saturday, October 14, 2023
Session Time: 1:30-3:00 p.m. PT
Author/Presenter: I-Ping Chen, D.D.S., Ph.D. (Associate Professor, Oral Health and Diagnostic Sciences, UConn Health)

About ENPP1 Deficiency

ENPP1 Deficiency is a progressive condition that manifests as a spectrum of diseases. Individuals who present in utero or in infancy are typically diagnosed with generalized arterial calcification of infancy (GACI), which is characterized by extensive vascular calcification and intimal proliferation (overgrowth of smooth muscle cells inside blood vessels), resulting in myocardial infarction, stroke, or cardiac or multiorgan failure. Approximately 50% of infants with ENPP1 Deficiency die within six months of birth. Children with ENPP1 Deficiency typically develop rickets, a condition diagnosed as autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adolescents and adults can develop osteomalacia (softened bones). ARHR2 and osteomalacia lead to pain and mobility issues. Patients can also exhibit signs and symptoms of hearing loss, arterial and joint calcification, and cardiovascular complications. There are no approved therapies for ENPP1 Deficiency.